Medikinet Retard

Methylphenidate, the active ingredient in Medikinet Retard, is a central nervous system stimulant presented as an extended-release tablet for oral use. It treats attention deficit hyperactivity disorder (ADHD) and narcolepsy in children, adolescents, and adults. GNH USA supplies Medikinet Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Medikinet Retard, a central nervous system stimulant, is indicated for conditions involving attention regulation and wakefulness.

ADHD (children and adolescents): improves attention, reduces hyperactivity and impulsivity. ADHD (adults): enhances focus and reduces distractibility. Narcolepsy: decreases excessive daytime sleepiness and improves wakefulness.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced hunger leading to weight loss. - Headache: mild to moderate head pain. - Nausea: feeling of sickness or urge to vomit. Serious or Rare Side Effects: - Cardiovascular events: chest pain, hypertension, or arrhythmia. - Psychosis: hallucinations or delusional thinking. - Severe allergic reaction: rash, swelling, or breathing difficulty.

Medikinet Retard requires careful clinical assessment before and during therapy. - Cardiovascular assessment: evaluate history of heart disease or hypertension before initiating treatment. - Psychiatric monitoring: watch for emergence or worsening of psychosis, mania, or anxiety. - Growth monitoring: regularly assess height and weight in pediatric patients. - Abuse potential: consider risk of dependence, especially in patients with a history of substance misuse. - Store at ambient temperature: keep below 25°C, protect from moisture and keep in the original packaging.

Medikinet Retard may interact with several medication classes. Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis when combined. - Antipsychotics: may diminish stimulant efficacy and increase side‑effect burden. - Blood pressure agents: additive cardiovascular effects may occur. Moderate Interactions (Monitor Closely): - SSRIs and other serotonergic drugs: potential for increased serotonin levels. - Antacids: may affect absorption of the extended‑release formulation. - Alcohol: can enhance central nervous system stimulation and increase adverse effects.